short title: CEACAM1 regulation of monocyte IL6 response to LPS ABSTRACT Systemic inflammation and the fever response to pathogens are coordinately regulated by IL-6 and IL-1β. We previously showed that CEACAM1 regulates the LPS driven expression of IL-1β in murine neutrophils through its ITIM receptor. We now show that the prompt secretion of IL-6 in response to LPS is regulated by CEACAM1 expression on bone marrow monocytes.
INTRODUCTION
IL-6 is a central mediator of inflammation in response to a wide variety of stimuli including infection, stress and trauma 1 . Its receptor, IL-6R, is widely expressed, especially in the liver leading to the acute phase protein response 1 , in the hypothalamus together with IL-1β leading to systemic fever 2 , and in the gut leading to Th17 activation 3 . Chronic high levels of IL-6 are associated with aging, cancer, rheumatoid arthritis, neurodegenerative diseases, postmenopausal osteoporosis 4 , and psoriasis 5 to name a few pathogenic conditions. As a result, activation of the IL-6 gene is under tight control, and an understanding of its regulation is fundamental to preventing a wide range of pathologies 6 . We are especially interested in the regulation of the fever response that requires production of both IL-1β and IL-6, that together stimulate the production of PGE2 in the hypothalamus leading to a drop in the core temperature of a few tenths of a degree 7 . Even more pronounced is the lowering of skin temperature that is perceived as "chills" followed by stimulation of the skeletal muscles or "shivering." The critical role of IL-6 in the fever response is exemplified in IL-6 KO mice that do not exhibit a fever in response to classical stimuli such as bacterial endotoxin, viruses, and the inflammatory cytokines TNFα and IL-1β 8 .
Given the wide range of stimuli that elicit the IL-6 response from essentially anywhere in the body, knowledge of the cells and mechanism of IL-6 secretion is essential. However, more is known about the cells that respond to IL-6 than those that produce it, and its regulation remains an area of intense investigation. We hypothesize that this regulation must be widespread, especially at the interface between the epithelium where infections, trauma and stress are likely to occur, and the immune system. A candidate gene for this regulation is CEACAM1, a homotypic cell-cell adhesion molecule ubiquitously expressed in the epithelium, constitutively expressed in neutrophils, the most abundant leukocytes, and inducibly expressed in activated lymphocytes 9 . CEACAM1 has tissue specific, differential expression of mRNA slice forms, with an ITIM containing signaling domain expressed in the immune system and a shortened signaling domain lacking an ITIM in uninflamed epithelial cells 10 . Notably, the expression of the ITIM containing CEACAM1 splice form is strictly regulated in response to IFN via IRF-1 11 . In agreement with this role for CEACAM1, we have previously shown that CEACAM1 regulates granulopoiesis and the systemic response to Listeria monocytogenes infection via the G-CSFR-STAT3 pathway 12 , and the IL-1β response to LPS in neutrophils by a TLR4-Syk pathway 13 . In both cases, CEACAM1 is recruited to an activated receptor (G-CSFR or TLR4), that when phosphorylated by a Src kinase on its ITIM, recruits SHP-1, which in turn, dephosphorylates the activated receptor. This is a general mechanism for CEACAM1 that has been implicated in the regulation of the insulin receptor in the liver 14 , the EGFR in epithelial cells 15 , and the BCR in B-cells 16, 17 . In this way, CEACAM1 can moderate the effect of the immune system on stimulated epithelial cells, and when absent, as in many cancers 18, 19 , the result is chronic or exaggerated inflammation. The digestive tract, including the small and large intestine, and the liver, have the highest levels of CEACAM1 expression 20 . Since it is well known that LPS in the peritoneal cavity, mimicking leaky gut, leads to a rapid inflammatory and fever response 21 due to the combined actions of IL-6 and Il-1, we speculated that an exaggerated response would be seen in CEACAM1 -/mice, providing a model system to track down the cells responsible for IL-6 release.
The plasma levels of IL-6 in Ceacam1 -/mice in response to i.p. LPS were more than twice the amount of wild type mice at 24-48 hours, including the depression of body surface temperatures and overt diarrhea in 50% of the Ceacam1 -/mice compared to none in the wild type controls. PET image analysis of mice injected i.p. with 64 Cu-labeled-LPS exhibited LPS localization confined to the peritoneal cavity, while i.p. injection of fluorescent tagged LPS demonstrated staining in the spleen, lymph nodes and endothelial cells of skeletal muscle.
Analysis of bone marrow cells revealed that a subset of bone marrow myeloid cells were rapidly
mobilized to the spleen, perhaps explaining the controversy over the lack of IL-6 secreting myeloid cells in mice treated with LPS. In vitro analysis revealed that bone marrow monocytes and their progenitors produce IL-6 in the early response (<2 hours) to LPS while tissue macrophages do not. Unexpectedly, we found that TLR4, the prototypic LPS receptor of murine macrophages 22, 23, 24 and human monocytes and macrophages 25, 26 was not expressed on murine bone marrow monocytes. Instead, the alternate LPS receptor RP105, highly expressed on B-cells, was responsible for IL-6 secretion on murine bone marrow monocytes. We demonstrated that MD1, CD14, Src, VAV1 and β-actin are involved in the signaling of RP105 and that CEACAM1 regulates RP105 signaling through recruitment of SHP-1 and sequestration of pVAV1 and β-actin from pRP105 to control IL-6 producing. We conclude that CEACAM1 negatively regulates IL-6 producing in the early phase response to LPS through the RP105 signaling pathway in murine monocytes, thus defining a novel role of CEACAM1 for monocytes in the fever response.
RESULTS

Genetic ablation of CEACAM1 leads to an exaggerated IL-6 response to LPS.
We previously showed that CEACAM1 regulates IL-1β production in LPS treated granulocytes in a TLR4-Syk specific manner 13 . Since IL-1β and IL-6 together mediate the fever response to LPS, we performed an in vivo challenge of wild type (WT) and Ceacam1 -/mice with LPS injected i.p. Surface body temperature was measured as a sensitive indicator of the fever response along with serum multiplex cytokine levels to determine which, if any, were dysregulated in Ceacam1 -/mice treated with LPS. Phenotypically, both WT and Ceacam1 -/mice had depressed surface body temperatures, with the depression in Ceacam1 -/mice significantly lower than in WT mice at both the 8hr and 24hr time points (Fig 1A) . 53% Ceacam1 -/mice (9 out of 17) developed overt diarrhea in comparison with none in wild type mice (Fig 1B) . Comparison of the serum levels of cytokines between Ceacam1 -/and WT mice, revealed similar kinetics and levels for IL-1β, TNFα and IFNγ, as well as others not shown, while IL-6 levels were significantly elevated in Ceacam1 -/mice over 24 hours, returning to baseline by 48 hours (Fig 1C-F) . The results suggest that abrogation of CEACAM1 expression in mice dramatically increases their sensitivity to i.p. LPS by specific over-expression of IL-6.
LPS distribution after i.p. injection and IL-6 mRNA expression in mouse organs
IL-6 is considered the critical proinflammatory cytokine for the febrile response, since neither IL-6 knock-out mice, nor animals treated with IL-6 antiserum develop fever upon peripheral immune stimulation 8, 27, 28 . Furthermore, it is understood that IL-6 acts in concert with IL-1β as an endogenous pyrogen during LPS-induced fever 7, 27 . Although IL-6 is reported to be synthesized and secreted by many cell types, for example, monocytes and macrophages 29, 30 , fibroblasts 31 , brain endothelial cells 32, 33 , muscle cells 34 , hepatocytes 35, 36 , adipocytes 37 , neurons 38, 39 , microglial cells 40, 41 and astrocytes 42, 43 , the source of serum IL-6 after i.p. treatment of LPS remains controversial 44 . As a first approach to determining the source of systemic production of IL-6, we injected 64 Cu-labeled LPS i.p. into mice and performed PET imaging (Fig 2A) . This approach allows a quantitative measure of LPS localization over time.
The results demonstrate that, excluding bladder secretion, 64 Cu-DOTH-LPS is mainly localized to the peritoneal cavity, including liver, kidney and thoracic lymph nodes at 1, 2, and 4 hour time points, and is largely cleared via urinary excretion by 24 hours. Notably, very little bone activity was observed, indicating that secretion of IL-6 by bone marrow cells (if any) must be indirect.
Utilizing a similar chemical procedure to produce a fluorescent version of LPS, we generated FAM-labeled LPS that is considerably brighter and more stable than commercially available FITC-LPS. Thus, as a second approach to visualizing tissue targets of LPS, FAM-LPS was injected i.p. and multiple tissues collected for analysis by immunofluorescence analysis at 1 hour. The results demonstrated high uptake into the spleen, lymph nodes, and the endothelial cells of skeletal muscle (Fig 2B, 2D) . Further analysis of the spleen cells labeled indicated that they were macrophages (Fig 2C) .
Since the first two approaches only indicate tissues of LPS uptake and not IL-6 production, we also measured IL-6 mRNA by qPCR of peritoneal tissues and other organs.
Most peritoneal cavity tissues/organs including mesentery, peritoneal membranes, pancreas, and fatty tissues did not show any difference between WT and Ceacam1 -/mice, while omentum and small intestine exhibited a decrease in Ceacam1 -/mice (Fig S1) . Surprisingly, skeletal muscle, lung, and kidney also exhibited significant decreases in the IL-6 mRNA expression compared to WT counterparts, while brain, bone marrow cells and mesenteric lymph nodes had no difference. The organs with significantly increased levels of IL-6 mRNA in Ceacam1 -/mice in comparison with WT mice were liver and spleen (Fig 3A) . Given the large size of the liver, the tentative conclusion is that liver may be the main IL-6 producer in response to i.p. LPS, followed by the spleen.
Liver cells and splenocytes are not the source of IL-6 in early response to LPS
To explore the role of liver and spleen in the secretion of IL-6 in response to LPS, liver cells (from PBS perfused liver to remove blood cells) and splenocytes from untreated mice to determine which cells, if any, produce IL-6 in direct response to LPS in vitro. Our results showed that IL-6 mRNA expression of liver cells and splenocytes after treated with LPS for 2 hours were not different between WT and Ceacam1 -/mice (Fig 3B) . When isolated hepatocytes or Kupffer cells were treated with LPS plus BFA (brefeldin A) for 5 hours, hepatocytes from Ceacam1 -/mice were negative for both IL-6 and TNFα (Fig S2A) while Kupffer cells were positive for TNFα only ( Fig S2B) . Furthermore, the IL-6 secretion of liver cells in response to LPS treatment was not significant difference between the two mouse strains until after 6 hours (Fig S3A) .
Based on these results, we surmised that IL-6 production observed for the liver (Fig 3A ) was due to blood cells trapped at the time of sacrifice. Therefore, the analysis was repeated on liver perfused after i.p. LPS treatment. There were no differences in IL-6 mRNA levels between WT and Ceacam1 -/mice (data not shown), suggesting that blood cells trapped in the liver, rather than endogenous cells were responsible for the observed difference (Fig 3A) . Western blot analysis of phospho-gp130, the key activation signal transducer of the IL-6 receptor, revealed that livers of both WT and Ceacam1 -/mice had similar levels after LPS treatment ( Fig   S3B) . The same was true for the downstream effectors of the gp-130, pSTAT1, pSTAT3 and SOCS3 (Fig S3B) . We conclude that although the liver is a major organ responsive to IL-6, it is not the main source of IL-6 in the early response to LPS.
A subgroup of bone marrow CD11b + Ly6Gmyeloid cells secrete IL-6 and are mobilized in the early response to LPS Since it was likely that the source of the IL-6 producing cells in the liver and spleen originated from the bone marrow, we collected bone marrow cells from untreated mice and determined their in vitro production of IL-6 in response to LPS. This analysis revealed significantly higher levels of IL-6 mRNA for Ceacam1 -/vs WT bone marrow cells in response to LPS (Fig 3C) .
Analysis of cell surface markers of bone marrow cells together with intracellular IL-6
staining after LPS treatment revealed that a subgroup of CD11b + Ly6Gcells but not CD11b + Ly6G + cells (granulocytes) or B220 + cells (B lymphocytes) produced IL-6 ( Fig 3E) .
Notably, there was no significant difference in CD11b + Ly6Gcell percentages of bone marrow cells between WT and Ceacam1 -/mice (Fig 3D) , suggesting that the number of IL-6 producing cells in the bone marrow per se are not responsible for the IL-6 differences observed in between WT and Ceacam1 -/mice. In accordance with the negative finding of IL-6 mRNA in bone marrow cells treated with LPS in vivo (Fig 3A) , intracellular staining of IL-6 was negative in bone marrow cells after i.p. injection of LPS plus BFA (Fig 3F) , but positive in one subgroup of CD11b + Ly6Gcells in the spleen (Fig 3G) . These results suggest that IL-6 producing bone marrow cells were mobilized from the bone marrow to the spleen after i.p. LPS treatment and that the subgroup of CD11b + Ly6Gcells may be responsible for the difference of IL-6 production between WT and Ceacam1 -/mice after LPS challenge.
Monocytes and the progenitors of myeloid CD11b + Ly6Gcells are IL-6 producing cells in the early response to LPS.
Since CD11b + Ly6Gcells in the bone marrow include different groups of myeloid cells, further analysis of cell surface markers was performed to clarify which cell type was responsible for IL-6 production. Recent studies have characterized bone marrow CD115 (M-CSF-R) positive cells into monocytes (Mo), common monocyte progenitors (cMoP), monocyte-macrophage DC progenitors (MDP) and common DC precursor (CDP) according to cell surface markers CD117 (c-Kit) and CD135 (FLT-3) 45 . Cell surface staining showed that all of four populations are CEACAM1 positive in WT mice ( Fig S4A) .
After in vitro treatment of bone marrow cells with LPS, CD115 expression was down-
regulated while the staining pattern of MDP, cMoP, Mo and CDP were indistinguishable ( Fig   S4B) . Therefore, the four populations of MDPs (Lin -CD115 + CD117 + CD135 + ), cMoP (Lin -CD115 + CD117 + CD135 -), Mo (Lin -CD115 + CD117 -CD135 -), and CDP (Lin -CD115 + CD117 -CD135 + ) were sorted (Fig 4A) and treated with LPS plus BFA for 5 hours. In WT mice, cMoP and Mo but not MDP and CDP were IL-6 positive. Surprisingly, in Ceacam1 -/mice, cMoP, Mo, and MDP but not CDP were all positive for IL-6 with significantly increased percentages over WT (Fig 4E-F ). There were no significant differences in the percentages of Lincells (Fig 4B) , CD115 + cells (Fig 4C) , nor the MDP, cMoP, Mo, and CDP subsets between WT and Ceacam1 -/mice ( Fig 4D) . These analyses show that monocytes and their progenitors are the major IL-6 producing cells in the bone marrow in the early response to LPS, and that the absence of CEACAM1 results in high levels of IL-6 production.
Macrophages do not produce IL-6 in the early response to LPS
Since monocytes and macrophages differ in their ability to process pro-IL-1β and release mature IL-1β 46, 47 , it was necessary to determine if a similar situation occurred for IL-6 production and secretion in macrophages. Peritoneal cavity macrophages, isolated from WT and Ceacam1 -/mice, were treated in vitro with LPS for 2, 4 and 24 hours. The results showed that there is no difference in IL-6 mRNA levels between WT and Ceacam1 -/mice at the 2 hour time point, but IL-6 mRNA levels significantly increased at the 4 hour time point and decreased at the 24 hour time point in Ceacam1 -/mice (Fig S5A) . When splenocytes from Ceacam1 -/mice were treated with LPS plus BFA for 5 hours, all three groups of myeloid cells (Ly6G -CD11b + cells), granulocytes (Ly6G + CD11b + cells), and lymphocytes (Ly6G -CD11bcells) were negative for IL-6 by intracellular staining (Fig S5B) . Similar results were obtained for WT mice (data not shown). Furthermore, the murine macrophage cell line RAW264.7 treated with LPS plus BFA for 5 hours was negative for intracellular IL-6 production (Fig S5C) . In fact, RAW264.7 cells treated with LPS showed that TNFα rather than IL-6 mRNA significantly increased at 2 hours in comparison with untreated controls, and that IL-6 mRNA levels only started to increase at the 4 hour time point, maintaining the increase through the 24 hour time point (Fig S5D) . The release of IL-6 into the supernatant after LPS treatment was delayed until the 24 hour time point but not at the early 2 hour time point (Fig S5E) . Intracellular IL-6 staining analysis showed that these cells began to produce IL-6 only after 11 hours of LPS treatment (Fig S6A) . Furthermore, silencing of CEACAM1 with siRNA in RAW264.7 cells did not affect IL-6 secretion at the 2 hour time point (Fig S6B) . Another murine macrophage cell line, J774A.1, exhibited similar results as RAW264.7 cells, i.e., there was no IL-6 production within 5 hours after LPS treatment and CEACAM1 siRNA did not interfere with IL-6 production (Fig S7) . Moreover, Kupffer cells in the liver (analyzed above, Fig S2B) gave similar results as did spleen macrophages (Fig S5B) .
These data indicate that although macrophages are derived from either monocytes or the yolk sac and are self-replenished 48 , they are unable to synthesize and release IL-6 in the early phase (<2 hours) of the LPS response.
To further explore the early response to LPS treatment, the time course of IL-6 mRNA was measured in bone marrow monocytes. As shown in Fig 5A, IL-6 mRNA is significantly increased as early as 30 minutes after LPS treatment and reached a peak at 90 min in Ceacam1 -/mice. These data confirm that monocytes are the main source of IL-6 in the early response to LPS and that CEACAM1 regulates this response. Given the report that an IL-6 feed-forward loop can increase IL-6 production 49, 50 , Il6ra -/mice and Stat3 flox/flox mice were included in our study. The analysis of IL-6 mRNA expression of bone marrow monocytes from Il6ra -/mice (Fig 5A) and Stat3 flox/flox mice (Fig 5B) demonstrated that a different expression pattern compared to the Ceacam1 -/mice over the time course of LPS treatment. These results suggest CEACAM1 expression does not interfere with the IL-6 receptor signal pathway, but only in the response to LPS.
TLR4 is not expressed on murine bone marrow monocytes
Having identified bone marrow monocytes as the source of prompt IL-6 secretion in response to LPS, we proceded to analyze the mechanism of CEACAM1 regulation. Since our previous studies showed CEACAM1 regulated TLR4 signaling in murine neutrophils, we expected a similar mechanism in murine monocytes, especially since human monocytes express abundant amounts of TLR4 26 . TLR4, the canonical LPS receptor, signals through the MyD88-and Toll/IL-1R domain-containing adapter inducing IFN-β (TRIF)-dependent upstream signals that lead to the production of proinflammatory (IL-6 and IL-1β) and anti-inflammatory mediators (IFN-β, IFN-α, CCL5), respectively 51, 52 . However, unlike IL-6 mRNA production in LPS treated murine monocytes, there was no change in the levels of IFN-β, IFN-α, and CCL5 mRNA at the 30 minute time point in WT, Ceacam1 -/-, and Il6ra -/mice. IFN-β, IFN-α,and CCL5 mRNA levels began to increase after 60 minutes but did not exhibit differences between WT and Ceacam1 -/mice at both the 60 and 90 minute time points. These results suggests that the TRIF-dependent signaling pathway, as one of two main signaling pathways of TLR4, was not directly involved in the response of murine bone marrow monocytes to LPS. Furthermore, TLR4 expression was negative on bone marrow monocytes from both WT and Ceacam1 -/mice using anti-TLR4 antibody surface staining (Fig 5C) and western blot analysis (Fig 5D) even though TLR4 mRNA was detected at low levels by qPCR (Fig 5E) . When RAW264.7 macrophage lineage cells were used as a positive control, TLR4 was easily detected by both surface staining and western blot analysis. On the other hand, CD14 that acts as an LPS co-receptor for TLR4, was strongly positive for bone marrow monocytes (Fig 5C) . We also performed intracellular immunofluorescent staining to explore the possibility that TLR4 was localized to intracellular granules, but the monocytes were negative (data not shown). In addition, TLR4 blocking antibody and the TLR4 inhibitor C34 did not interfere with LPS-induced IL-6 mRNA expression in these cells treated with LPS (Fig 5F) . Taken together, we conclude that TLR4 is not expressed on murine bone marrow monocytes and that TLR4 signaling is not responsible for the observed IL-6 production of murine monocytes.
RP105 (CD180) on bone marrow monocytes is the LPS receptor responsible for the early
IL-6 response to LPS
In consideration of alternative receptors for LPS, it is well known that B-cells respond strongly to LPS 53 . B-cells have two distinct LPS receptor complexes, TLR4/MD2 and RP105/MD1 54 . The extracellular domains of TLR4 and RP105 associate with MD2 and MD1, respectively, to form heterodimers, thereby forming the binding sites to LPS 54, 55 . Although we did not detect TLR4 on murine monocytes, RP105 and MD1 were highly expressed on bone marrow monocytes from both WT and Ceacam1 -/mice (Fig 5C) . Since the signaling pathway for RP105 has been extensively studied and involves recruitment of VAV1 and β-actin 54, 56 , we performed a number of co-IP studies on murine bone marrow monocytes treated with LPS.
MD1 co-IPed with RP105 in the presence or absence of LPS in bone marrow monocytes (Fig   6A) , while RP105 co-IPed with pVAV1 and β-actin in the absence of LPS in WT and Ceacam1 -/mice (Fig 6B) . After treatment with LPS, pVAV1 and β-actin dissociated with RP105 in WT mice, but in Ceacam1 -/mice, pVAV1 and β-actin remained associated with RP105. IP of CEACAM1 in WT mice co-IPed β-actin after LPS treatment (Fig 6C) . These results suggest that CEACAM1 can sequester pVAV1 and β-actin from RP105 after LPS treatment thus negatively regulating RP105 downstream signaling. In the absence of CEACAM1, RP105 remains associated with pVAV1 and β-actin resulting in increased downstream signaling. Furthermore, the VAV1 inhibitor azathioprine, and a metabolite of azathioprine, 6-thio-GTP, was able to block the IL-6 mRNA over-response to LPS in Ceacam1 -/mice (Fig 6D) . Moreover, an RP105 activating monoclonal antibody 57 was able to stimulate IL-6 mRNA expression in WT mice and IL-6 mRNA over-expression in Ceacam1 -/mice similar to LPS treatment (Fig 6E) . On the other hand, blocking antibodies to MD1 or CD14 completely abrogated LPS-induced IL-6 mRNA expression in both WT and Ceacam1 -/mice (Fig 6F) . Furthermore, CD14 was co-IPed with RP105 (Fig 6G) . We conclude that the RP105/MD1/CD14 complex on murine bone marrow monocytes is responsible for the early phase expression of IL-6 in LPS treated mice, and CEACAM1 negatively regulates RP105 signaling in response to LPS stimulation.
It was reported that Lyn phosphorylation and its kinase activity were involved in RP105 signaling in B cells 54 . In our study of mouse monocytes, when RP105 was IPed, we did not detect Lyn, but instead, we found RP105 co-IPed with Src (Fig 6G) . A selective and competitive dual site Src inhibitor (Src l1) was able to block the over-response of IL-6 mRNA expression to LPS in Ceacam1 -/mice (Fig 6H) . This suggests that Src, but not Lyn, is the kinase involved in RP105 mediated LPS signaling in murine monocytes.
We have previously shown that CEACAM1 act as an inhibitory B-cell co-receptor through recruitment of the inhibitory tyrosine phosphatase SHP-1 16 . Suspecting a similar inhibitory mechanism in LPS treated monocytes, we IPed CEACAM1 in LPS treated monocytes and performed western blot analysis with anti-phosphotyrosine and anti-phospho-SHP-1 antibodies (Fig 6I) . The results demonstrate that CEACAM1 is phosphorylated on tyrosine after LPS treatment (Fig 6I upper) , that phospho-SHP-1 is co-IPed with CEACAM1, and the levels of phhospho-SHP1increase after treatment with LPS (Fig 6I lower) . Furthermore, treatment of bone marrow monocytes with LPS in the presence of SHP1 inhibitor, PTP inhibitor III, increases phospho-VAV1 in WT but not in Ceacam1 -/mice mice (Fig S8) . These results show that RP105 stimulation by LPS leads to recruitment of SHP-1 to CEACAM1, a result that limit tyrosine phosphorylation of both VAV1 and RP105 by Src. Thus, murine monocytes may share a common signaling pathway with B-cells since they both express CEACAM1 and RP105.
DISCUSSION
IL-6 is a soluble mediator with a pleiotropic effect on inflammation, immune response
and hematopoiesis affecting vascular disease, lipid metabolism, insulin resistance, mitochondrial activities, the neuroendocrine system and neuropsychological behavior 58 . In this study, we focused on the role of CEACAM1 in the regulation of IL-6 production. Rather surprisingly, we found that bone marrow monocytes and not peripheral macrophages were responsible for the early IL-6 response to i.p. LPS. Although there was an increase of IL-6 mRNA expression in macrophages after 2 hours, secreted IL-6 occurred much later and was likely due to the early production of TNF by these cells. Moreover, the bone marrow monocytes responsible for IL-6 production as shown by in vitro analysis, were not detected in the bone marrow of mice treated in vivo with LPS, demonstrating their rapid mobilization to the periphery. For example, analysis of the liver of LPS treated mice revealed that the source of IL6 was in the blood rather than in isolated hepatocytes or Kupffer cells. In accordance with this finding, it was earlier reported that low concentrations of Toll-like receptor (TLR) ligands in the bloodstream drive CCR2-dependent emigration of monocytes from the bone marrow 59 . In other results, we found that the CCR2 ligand, CCL-2 was elevated in both WT mice and Ceacam1 -/mice treated with LPS, with the higher levels in Ceacam1 -/mice (data not shown).
The discovery of TLR family proteins was particularly critical in showing the importance of innate immunity in the host defense against microbial infection. TLRs are characterized by extracellular leucine-rich repeat (LRR) motifs and intracellular Toll/interleukin 1 receptor (TIR) domains 52 . TLR4 is a well-known pathogen recognition receptor that plays a key role in the prototypical inflammatory stimulus to LPS 60 . LPS engagement of TLR4 initiates a cascade of signaling events via intracellular Toll/IL-1R signaling domains, that involve the primary recruitment of the Mal adaptor protein and its subsequent association with My88 to ultimately promote the activation of the NF-κB transcriptional complex and induction of many proinflammatory cytokine genes, such as IL-6, TNFα, and IL-1β. Host immune responses triggered by TLR4 also involve the recruitment of other intracellular signaling adaptors, in particular, TRIF and TRIF-related adaptor molecule, which also facilitate activation of NF-κB and IRF3 (IFN regulatory factor 3), the latter of which promotes the transcription of proinflammatory type I IFN genes 61 . Unexpectedly, our results demonstrated that TLR4 protein is not expressed on murine bone marrow monocytes as evidenced by lack of activation of the TRIF-dependent pathway, absence of TLR4 protein and lack of effect on IL6 production by a TLR4 blocking antibody or TLR4 inhibitor C34. Although it is well known that TLR expression is high on human monocytes, many murine cells of myeloid origin, including macrophages, microglia, myeloid DCs, and granulocytes have been reported to have high levels of TLR4 expression 62 . However, the status of TLR4 expression in murine monocytes, neither TLR4 mRNA nor TLR4 protein was shown 63 .
In contrast, mouse macrophages, as well as the two macrophage cell lines RAW264.7 and J774A.1, express TLR4 on their cell surface. However, neither of these cell lines, nor peripheral murine macrophages, exhibited an early IL-6 response to LPS (< 2 hours). Thus, most studies on LPS stimulated TLR signaling in the mouse are limited to macrophages, while in human, both monocytes and macrophages are used. A further source of confusion, relevant to our study is that mouse monocytes are CEACAM1 + and TLR4 -(our data) while human monocytes are CEACAM1and TLR4 + (Fig S9) . Notably, when we generated a human Ceacam1 transgenic (TG) mouse using the complete human CEACAM1 genome 64 and crossed them into the Ceacam1 -/background, bone marrow monocytes in the hCeacam1 TG mice did not express hCEACAM1 protein (data not shown).
The finding that TLR4 negative murine bone marrow monocytes were responsible for the prompt IL6 response to LPS necessitated a search for an alternative LPS receptor. The obvious candidate, RP105, was first reported in 1995 as a LRR protein expressed on B cells 65 . Although TLR4-deficient mice. Third, although LPS appears to bind to MD-1 with lower affinity than to MD-2 67 , the RP105/MD-1 complex is expressed not only on B cells but also on macrophages and dendritic cells 68 . We now report that the RP105/MD1 complex is also expressed on murine bone marrow monocytes and is negatively regulated by CEACAM1 as evidenced by sequestrating pVAV1 and β-actin from pRP105 in WT mice and the increased association of RP105 with pVAV1 and β-actin in CEACAM1 -/mice. The involvement of pVAV1 and -actin in LPS stimulated RP105 signaling in B-cells has been previously reported 55 . Furthermore, we show that CEACAM1 in murine monocytes is phosphorylated on tyrosine and recruits the inhibitory tyrosine phosphatase SHP1 after treatment of with LPS, a finding similar to our previous studies on murine neutrophils treated with LPS 12 . More importantly, CEACAM1, itself an actin recruiting receptor 69 , competes with VAV1 for actin recruitment, thus diminishing the ability of VAV1 to signal downstream to mediators such as NFkB, required for IL-6 expression.
The dramatic sequestration of actin away from VAV1 is shown in Fig 6C. The overall model for LPS/RP105 signaling in murine monocytes in shown in Fig 7. It is well-known that macrophages and dendritic cells are monocyte-differentiated cells that express both TLR4/MD2 and RP105/MD1. In agreement with our finding that macrophages are more tuned to LPS/TLR4 signaling, RP105-or MD-1-deficient macrophages are not impaired in TNFα production induced by the lipid A moiety of LPS 68 . While DCs from RP105deficient mice produced significantly higher concentrations of proinflammatory cytokines after stimulation with LPS, the RP105/MD-1 complex competes with the binding of LPS to the TLR4-MD-1 complex and negatively regulate LPS-TLR4-mediated responses in dendritic cells 70 . If TLR4 is a high affinity receptor for LPS while RP105 a low affinity receptor, the differential expression between macrophages/dendritic cells and murine bone marrow monocytes may be a fine-tuning mechanism to prevent an over-response to LPS, in this case, initiation of the fever response. Moreover, peripheral blood monocytes, acting as adult stem cells, are capable of undergoing maturation into several types of tissue-resident macrophages, including tissue resident macrophages, Kupffer cells, Langerhans cells of the skin, dendritic cells, microglia, and osteoclasts 71 . In the process of their tissue differentiation their requirement for sensitivity to LPS may change.
A major finding of our study is that CEACAM1, previously shown to regulate LPS signaling in neutrophils, also regulates LPS signaling in monocytes, but in the case of neutrophils the inhibitory regulation is through TLR4 12 , while in monocytes through RP105. In both cases, recruitment of the inhibitory tyrosine phosphatase SHP1 is involved, suggesting that the ITIM sequence in CEACAM1 12 plays a major role in dampening immune responses in a wide variety of immune cells. Indeed, that is also the case for B-cells 16 and T-cells 19 . A second major finding of our study is that the prompt IL6 mediated fever response to LPS occurs through monocytes in the mouse and that it is negatively regulated by CEACAM1. Indeed, CEACAM1 -/mice experience hyper IL6 responses to LPS, included exaggerated surface temperature depression (the mice shiver and huddle together in their cages) and overt diarrhea in over 53% of the treated animals. Not surprisingly, IL-1, the other key regulator in the fever response, is also regulated by CEACAM1 12 . Thus, CEACAM1 plays an inhibitory role at two levels in the fever response, and may be a candidate drug target for fever reduction.
METHODS
Ethics statement.
This study was carried out in strict accordance with the recommendations of the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol (number 08017) was approved by the Institutional Animal Care and Use Committee (IACUC) of the City of Hope.
Mice Strains
Ceacam1-/-mice were generated by Nicole Beauchemin and coworkers (McGill University, Montreal, Canada). WT C57/B6 mice were purchased from Jackson laboratory (Bar Harbor, ME). IL-6Rα (CD126)-deficient (Il6ra −/− ) mice and Stat3 flox/flox mice were mentioned in the publication 72 . Mice 7-12 weeks old were used for all the experiments.
Synthesis, radiolabeling and PET imaging of DOTH-conjugated LPS and synthesis of
FAM-labeled LPS
LPS (10 mg, O55:B5 E. coli, Sigma-Aldrich) was made monomeric by treatment with 5 ml of 0.5% triethylamine (Sigma-Aldrich) and by sonication for 15 min on ice. After the sonication, 200 ml of LPS was removed from the solution and added to a tube containing NaIO4 (20ul,20mM, made freshly), pH 7.1. Excess NaIO4 was removed on a Zeba spin column (Thermo Scientific, IL.) after incubated 30min on ice, reacted with 26ul of DOTH (7.8mM in H2O, 202nmol), pH6.2, at RT for 2h., and then treated with 10ul of sodium cyanoborohydride (200mM in H2O, 2000nmol) at RT for 2h., followed by running a Zeba spin column again to remove excess DOTA and NaCNBH3. All reaction was protected from light 73 Technologies was used for detection of Regnase1. After denaturation for 3 min at 95⁰C, 40 cycles of amplification were performed (95ºC for 10s then 55ºC for 10s). Finally, melting curves were generated between 55ºC and 95ºC, for every 0.5ºC. All Ct values were normalized to GAPDH, and quantification of gene expression was calculated by using the ∆CT method.
Flow Cytometry and Cell Sorting
Bone marrow cells were flushed out using PBS with 2% FBS and red blood cells were Then, cells were harvested for qPCR or immunoblot analysis. For IL-6 release analysis, cells were treated with 500ng/mL LPS over time in the figure and supernatants were collected and analyzed using cytometric bead array. The concentration of inflammatory cytokines was measured using cytometric bead array (CBA; BD Biosciences, USA) as described previously 74 .
Bone marrow monocyte isolation and Cytokine cytometric bead assay
This assay is multiplexed and measures the concentration of each cytokine simultaneously.
Mean of fluorescence intensity were converted to cytokine concentration (pg/mL) using a standard curve for each cytokine measured. Graphs were plotted using GraphPad Prism.
Diarrheogenic activity and thermometry
The diarrheogenic activity was measured by observing wet area distance of tail from mouse anus. Any area more than 2 millimeters indicated positive diarrhea cases. 
Immunoblot analysis and immunoprecipitation (IP)
After 10mg/kg i.p. injection of LPS for 2 hours, Liver, spleen and duodenum of both WT and Ceacam1 -/mice were harvested separately, homogenized and lysed in 1% NP-40 lysis buffer as previously described 64 VAV1 pAb, SHP1 pAb, phospho-SHP-1 Y564 pAb, Src, and 4G10 pAb from Cell Signaling Technology, Inc., Danvers, MA; anti-β-actin mAb from GeneTex, Inc., Irvine, CA) and infraredlabeled IRDye secondary antibodies. Detection was carried out using the Odyssey infrared imaging 77 .
Statistical Analysis
Assay results were expressed as means ±SEM and paired or unpaired Student's t-tests were used for comparisons. All p-values are two-sided. Data were analyzed with GraphPad Prism software (version 5.0, GraphPad Software, San Diego, CA, USA). 
